#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute promyelocytic leukaemia Leiomyosarcoma metastatic Thalassaemia beta Barth syndrome Splenic marginal zone lymphoma Heart disease congenital Erythema multiforme Neurofibromatosis Small for dates baby Hepato-lenticular degeneration Colorectal adenocarcinoma Mucopolysaccharidosis III Chronic cutaneous lupus erythematosus Idiopathic inflammatory myopathy Dent's disease More trials…

    Learn about Rare Diseases

    Metachromatic leukodystrophy – Diagnostics Undifferentiated sarcoma IgA nephropathy – Diagnostics Usher’s syndrome – Trials in Disease Medulloblastoma recurrent – Treatment Progressive multifocal leukoencephalopathy – Diagnostics Paroxysmal nocturnal haemoglobinuria – Treatment Pleomorphic leiomyosarcoma – Life with Disease Mantle cell lymphoma refractory – Treatment Ornithine transcarbamoylase deficiency More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Esomeprazole Magnesium ALENDRONATE SODIUM TRIHYDRATE Relugolix Apocynin Dexamethasone Acetate Plitidepsin GRNA-001 Latanoprost Bromhexine Hydrochloride SALICYLIC ACID Pegunigalsidase Alfa VGA039 Duloxetine Surzebiclimab Efepoetin Alfa Fluoroestradiol F-18 OXYBUTYNIN HYDROCHLORIDE 64Cu-Dota-Ae105 Pioglitazone BRENSOCATIB More therapies…

    Learn about Your Condition

    Colour blindness Peritoneal sarcoma Varices oesophageal Testicular germ cell cancer Pancoast's tumour Large cell lung cancer Cervix carcinoma recurrent Hyperinsulinism Brain neoplasm HER2 protein overexpression Spinal osteoarthritis Renal cell carcinoma COVID-19 Cervix carcinoma stage IV Osteomyelitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Primary hyperoxaluria

  • Study on the Safety and Effects of ABO-101 with mRNA-002 and gRNA-001 for Patients with Primary Hyperoxaluria Type 1

    Recruiting

    2 1 1
    Investigated Diseases:
    • Primary hyperoxaluria
    Investigated Drugs:
    • GRNA-001
    France Germany The Netherlands

  • Study on Stiripentol for Patients Aged 6 and Older with Primary Hyperoxaluria Types 1, 2, or 3

    Recruiting

    3 1 1
    Investigated Drugs:
    • Stiripentol
    Belgium France Italy

  • Study of nedosiran for patients with primary hyperoxaluria type 1 and severe kidney impairment with or without dialysis

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Nedosiran
    Germany Italy Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!